Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMILY: Fulvestrant vs Capecitabine Maintenance in Metastatic Breast Cancer
NCT04263298Phase 3Recruiting
- Start
- May 2018
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fulvestrant in breast cancer (2 arms). Primary endpoint: Progression-Free Survival at 18 months. Started May 2018; status: recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04263298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263298.